Ultragenyx Pharmaceutical reported $6M in Interest Income for its fiscal quarter ending in March of 2026.





Interest Income Change Date
Acadia Pharmaceuticals USD 8.06M 277K Mar/2026
Agios Pharmaceuticals USD 10.8M 1.62M Mar/2026
Alnylam Pharmaceuticals USD 26.6M 32K Mar/2026
BioCryst Pharmaceuticals USD -0.13 3.59M Dec/2024
BioMarin Pharmaceutical USD 22.56M 3.35M Mar/2026
Immunic USD -0.24 0.03 Sep/2024
Insmed USD 765K 55K Sep/2024
Ionis Pharmaceuticals USD -0.66 0.29 Dec/2024
Karyopharm Therapeutics USD -0.15 0.11 Dec/2024
Kyowa Hakko Kirin JPY 2.54B 1.52B Jun/2024
MacroGenics USD 1.55M 26K Mar/2026
Moderna USD 72M 2M Mar/2026
Puma Biotechnology USD 0.41 0.5 Sep/2024
Regeneron Pharmaceuticals USD 183.3M 200K Jun/2026
Sarepta Therapeutics USD 7M 1.74M Mar/2026
Ultragenyx Pharmaceutical USD 6M 512K Mar/2026
Vertex Pharmaceuticals USD 120.6M 5.8M Jun/2026